Logo image
Aspergillus otomycosis in an immunocompromised patient
Journal article   Open access   Peer reviewed

Aspergillus otomycosis in an immunocompromised patient

Amy L Rutt and Robert T Sataloff
Ear, nose, & throat journal, v 87(11), pp 622-623
Nov 2008
PMID: 19006061
url
https://doi.org/10.1177/014556130808701107View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Antifungal Agents - therapeutic use Aspergillosis - diagnosis Aspergillosis - drug therapy Aspergillosis - microbiology Aspergillus niger - isolation & purification Clotrimazole - therapeutic use Earache Fluconazole - therapeutic use Humans Immunocompromised Host Male Middle Aged Tympanic Membrane - microbiology Tympanic Membrane - pathology Tympanic Membrane - surgery Tympanic Membrane Perforation - diagnosis Tympanic Membrane Perforation - microbiology Tympanic Membrane Perforation - pathology Tympanic Membrane Perforation - surgery
Aspergillus niger, an opportunistic filamentous fungus, was identified as the cause of chronic unilateral otomycosis in a 55-year old, immunocompromised man who had been unresponsive to a variety of treatment regimens. The patient presented with intermittent otalgia and otorrhea and with a perforation of his left tympanic membrane. A niger was identified in a culture specimen obtained from the patient's left ear canal. In immunocompromised patients, it is important that the treatment of otomycosis be prompt and vigorous, to minimize the likelihood of hearing loss and invasive temporal bone infection.

Metrics

14 Record Views
18 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Otorhinolaryngology
Logo image